About
Next-generation antibody-drug conjugates (ADCs), and targeted protein degradation (TPD) drugs
Areas of Focus
Categories
Biologics & BiopharmaceuticalSmall Molecule PharmaceuticalAntibodyChina
Clinical Trials (16)
View allTotal Trials
16
As Lead Sponsor
16
As Collaborator
0
Total Enrollment
2,916
By Phase
PHASE1/PHASE2: 6PHASE3: 3PHASE2: 1PHASE1: 6
By Status
COMPLETED: 7RECRUITING: 6NOT_YET_RECRUITING: 3
Clinical Trials Pipeline16 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06987500Lead Sponsor
A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
PHASE1/PHASE2Recruiting
132 participants
Started: Apr 11, 2025 · Completed: Aug 16, 2027
NCT06776952Lead Sponsor
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
PHASE3Not yet recruiting
120 participants
Started: Feb 4, 2025 · Completed: Apr 30, 2028
NCT06702605Lead Sponsor
To Evaluate XNW5004 Tablets in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
PHASE2Not yet recruiting
50 participants
Started: Nov 30, 2024 · Completed: Jan 31, 2027
NCT06799637Lead Sponsor
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
PHASE1/PHASE2Recruiting
200 participants
Started: Dec 1, 2023 · Completed: Dec 31, 2026
NCT06022757Lead Sponsor
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
PHASE1/PHASE2Recruiting
204 participants
Started: Sep 20, 2023 · Completed: Aug 31, 2028
Locations (1)
Headquarters
Beijing, China
Map
Loading map...